CLINTEC, Karolinska Institutet, Division of Pediatrics, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
Thromb Res. 2013 Sep;132(3):346-51. doi: 10.1016/j.thromres.2013.05.032. Epub 2013 Aug 30.
The international normalized ratio (INR) is used to prioritize liver disease patients for transplantation. Previous studies have shown high interlaboratory variability in Quick-based INR determinations in samples of patients with liver disease. We assessed Owren-based INR reagents for analyzing INR in patients with liver disease. Further, we determined the difference between international sensitivity index (ISI) for patients on vitamin K antagonists (ISIVKA) and ISI for patients with liver disease (ISIliver).
Twenty patients with liver disease were included, 10 with INR 1.8-3.6 (group A1) and 10 with INR 1.2-1.5 (group C1). Plasma from these patients was analyzed for Owren-based INR in eight Swedish laboratories using either of following reagents: SPA+, Owrens PT or Nycotest PT. To determine ISI liver, the reference thromboplastin RBT/05 and additional 41 patients with liver disease and 20 normal controls were included. ISIVKA was determined according to the WHO procedure. The difference between the ISIVKA and ISIliver was calculated.
The coefficients of variance for the Owren based INR methods were 6.2% in group A1, 3.9 % in group C1 and 5.3% for all patients. The difference between ISIVKA and ISIliver were -0.4%, -0.7% and -0.2% for SPA+, Owrens PT and Nycotest PT respectively.
Interlaboratory variation in INR analyses according to Owren in patients with liver disease is low and the difference between ISIVKA and ISIliver is below 10% with this method. ISIVKA can therefore be used in the INR calibration, for the Owren reagents studied, when analyzing plasma from patients with liver disease.
国际标准化比值(INR)用于优先考虑肝脏疾病患者进行移植。先前的研究表明,在肝脏疾病患者样本中,Quick 法 INR 测定存在高实验室间变异性。我们评估了 Owren 法 INR 试剂在肝脏疾病患者中的分析应用。此外,我们确定了维生素 K 拮抗剂患者的国际敏感指数(ISIVKA)和肝脏疾病患者的国际敏感指数(ISIliver)之间的差异。
纳入 20 例肝脏疾病患者,10 例 INR 为 1.8-3.6(A1 组),10 例 INR 为 1.2-1.5(C1 组)。这些患者的血浆在 8 个瑞典实验室使用 SPA+、Owrens PT 或 Nycotest PT 进行 Owren 法 INR 分析。为了确定 ISIliver,我们纳入了 41 例肝脏疾病患者和 20 例正常对照的参考凝血活酶 RBT/05。ISIVKA 按照世界卫生组织(WHO)的程序确定。计算 ISIVKA 和 ISIliver 之间的差异。
A1 组 Owren 法 INR 方法的变异系数为 6.2%,C1 组为 3.9%,所有患者为 5.3%。SPA+、Owrens PT 和 Nycotest PT 对应的 ISIVKA 与 ISIliver 之间的差异分别为-0.4%、-0.7%和-0.2%。
肝脏疾病患者 Owren 法 INR 分析的实验室间差异较小,使用该方法时 ISIVKA 与 ISIliver 之间的差异低于 10%。因此,当分析肝脏疾病患者的血浆时,Owren 试剂的 ISIVKA 可用于 INR 校准。